Skip to main content Back to Top
Advertisement

5/26/2016

METHOTREXATE INJECTION

Products Affected - Description

    • Methotrexate injection, Mylan Institutional, 25 mg/mL, 10 mL preservative-free vial, 1 count, NDC 67457-0466-10
    • Methotrexate injection, Mylan Institutional, 25 mg/mL, 2 mL preservative-free vial, 5 count, NDC 67457-0467-99
    • Methotrexate injection, Mylan Institutional, 25 mg/mL, 4 mL preservative-free vial, 10 count, NDC 67457-0486-99
    • Methotrexate injection, Mylan Institutional, 25 mg/mL, 40 mL preservative-free vial, 1 count, NDC 67457-0480-40
    • Methotrexate injection, Mylan Institutional, 25 mg/mL, 8 mL preservative-free vial, 10 count, NDC 67457-0485-99

Reason for the Shortage

    • Mylan Institutional cannot provide a reason for the shortage.
    • Sandoz discontinued methotrexate 2 mL and 10 mL vials.
    • Teva has methotrexate on short-term back order for standard quality control.
    • West-Ward Pharmaceuticals discontinued methotrexate injection in September 2014.

Available Products

    • Otrexup subcutaneous injection, Antares Pharm, Inc., 10 mg/0.4 mL, auto-injector, 4 count, NDC 54436-0010-04
    • Otrexup subcutaneous injection, Antares Pharm, Inc., 15 mg/0.4 mL, auto-injector, 4 count, NDC 54436-0015-04
    • Otrexup subcutaneous injection, Antares Pharm, Inc., 20 mg/0.4 mL, auto-injector, 4 count, NDC 54436-0020-04
    • Otrexup subcutaneous injection, Antares Pharm, Inc., 25 mg/0.4 mL, auto-injector, 4 count, NDC 54436-0025-04
    • Methotrexate injection, Accord, 25 mg/mL, 10 mL vial, 1 count, NDC 16729-0277-03
    • Methotrexate injection, Accord, 25 mg/mL, 2 mL preservative-free vial, 1 count, NDC 16729-0277-30
    • Methotrexate injection, Accord, 25 mg/mL, 40 mL preservative-free vial, 1 count, NDC 16729-0277-35
    • Methotrexate injection, Fresenius Kabi, 25 mg/mL, 10 mL (with preservative) vial, 1 count, NDC 63323-0123-10
    • Methotrexate lyophilized powder for solution for injection, Fresenius Kabi, 1 gram, vial, 1 count, NDC 63323-0122-50
    • Methotrexate injection, Pfizer, 25 mg/mL, 2 mL (with preservative) vial, 5 count, NDC 61703-0350-38
    • Methotrexate injection, Pfizer, 25 mg/mL, 40 mL preservative-free vial, 1 count, NDC 61703-0408-41
    • Methotrexate injection, Sandoz, 25 mg/mL, 40 mL preservative-free vial, 1 count, NDC 66758-0041-01
    • Methotrexate injection, Teva, 25 mg/mL, 10 mL preservative-free vial, 1 count, NDC 00703-3675-01
    • Methotrexate injection, Teva, 25 mg/mL, 2 mL preservative-free vial, 10 count, NDC 00703-3671-03
    • Methotrexate injection, Teva, 25 mg/mL, 40 mL preservative-free vial, 1 count, NDC 00703-3678-01

Estimated Resupply Dates

    • Mylan Institutional has all methotrexate presentations on back order and the company cannot estimate a release date.
    • All other suppliers have product available.

Updated

Updated May 26, 2016 by Michelle Wheeler, PharmD, Drug Information Specialist. Created February 8, 2012 by Jane Chandramouli, PharmD, Drug Information Specialist. Copyright 2017, Drug Information Service, University of Utah, Salt Lake City, UT.

Disclaimer

This information is provided through the support of Vizient to ASHP solely as a service to its members, which shall not use this information for their further commercial use. The content was prepared by the Drug Information Center of University of Utah. Vizient, ASHP, and the University of Utah make no representations or warranties, express or implied, including, but not limited to, any implied warranty of merchantability and/or fitness for a particular purpose, which respect to such information, and specifically disclaim all such warranties. Users of this information are advised that decisions regarding the use of drugs and drug therapies are complex medical decisions and that in using this information, each user must exercise his or her own independent professional judgment. Neither Vizient, ASHP nor the University of Utah assumes any liability for persons administering or receiving drugs or other medical care in reliance upon this information, or otherwise in connection with this bulletin. Neither Vizient, ASHP nor University of Utah endorses or recommends the use of any drug.

« Back to Drug Shortage Product Bulletins